GICS Sector : Healthcare
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States.It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Jun -11
Why Is DermTech (DMTK) Stock Down 26% Today?
Jun -24
Crude Oil Rises 1%; DermTech Shares Plummet
Jun -18
DermTech Files for Voluntary Chapter 11 Protection
Jun -18
DermTech Reports First-Quarter 2024 Financial Results
May -14
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
Apr -18
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
Mar -08
DermTech, Inc. (DMTK) Q4 2023 Earnings Call Transcript
Mar -01
Increasing incidence of melanoma, growing demand for non-invasive diagnostic tests, and advancements in genomic biomarkers drive growth in the DermTech Melanoma Test market.
Growing demand for non-invasive diagnostic tools, increasing skin cancer incidence, and advancements in genomic analysis drive the adoption of Smart Stickers, enabling early detection of skin cancers and other skin conditions.
Growing demand for non-invasive diagnostic tests, increasing skin cancer incidence, and advancements in RNA extraction technology drive the growth of DermTech's RNA extractions for skin cancer detection and other skin-related diseases.
Increasing adoption of digital health technologies, growing demand for non-invasive skin cancer detection, and advancements in AI-driven diagnostics drive growth in DermTech's project management for skin cancer detection and diagnosis.
A non-invasive, adhesive patch-based test that uses artificial intelligence to detect skin cancer, including melanoma, from a small skin sample.
A gene expression test that analyzes a skin sample to detect melanoma, the deadliest form of skin cancer.
A gene expression test that analyzes a skin sample to detect skin cancers, including basal cell carcinoma and squamous cell carcinoma.
DermTech's proprietary technology and strong patent portfolio reduce the threat of substitutes, but the company still faces competition from traditional biopsy methods.
DermTech's customers, primarily dermatologists and healthcare providers, have limited bargaining power due to the company's unique offerings and strong market position.
DermTech has a diversified supplier base, reducing dependence on any single supplier, and the company's strong financial position gives it negotiating power.
The threat of new entrants is high due to the growing demand for non-invasive skin cancer detection methods, but DermTech's strong patent portfolio and established market position provide a barrier to entry.
The intensity of rivalry is moderate due to the presence of competitors in the skin cancer detection market, but DermTech's unique technology and strong market position help to differentiate it from competitors.
| Value | |
|---|---|
| Debt Weight | 48.75% |
| Debt Cost | 3.95% |
| Equity Weight | 51.25% |
| Equity Cost | 16.74% |
| WACC | 10.50% |
| Leverage | 95.14% |
Value: 6.8
Growth: 6.7
Quality: 4.0
Yield: 0.0
Momentum: 9.5
Volatility: 1.0
1-Year Total Return ->
Value: 9.8
Growth: 3.2
Quality: 4.6
Yield: 0.0
Momentum: 3.5
Volatility: 0.3
1-Year Total Return ->
Value: 10.0
Growth: 3.3
Quality: 2.7
Yield: 0.0
Momentum: 5.0
Volatility: 0.3
1-Year Total Return ->
Value: 10.0
Growth: 4.7
Quality: 4.8
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->
Value: 9.8
Growth: 4.6
Quality: 4.0
Yield: 0.0
Momentum: 0.5
Volatility: 0.0
1-Year Total Return ->
Value: 9.8
Growth: 4.3
Quality: 3.0
Yield: 0.0
Momentum: 0.5
Volatility: 0.7
1-Year Total Return ->